Inside Precision Medicine October 18, 2023
Immunotherapies such as checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapies have revolutionized the field of oncology over the last few years, but they are just the beginning. A new wave of immunotherapies is now hitting the clinic.
In 2022, Immunocore’s tebentafusp (Kimmtrak) was the first TCR anti-cancer therapy to receive FDA approval. While most companies developing TCR therapies are using a method called phage display to design new treatments, ex-Immunocore scientist Michelle Teng and colleagues at Etcembly have developed a method of using generative AI to discover and design a range of different TCRs to fight cancer and other conditions. They have already developed a candidate bispecific T cell engager therapy, to target a cancer antigen known as...
Today's Sponsors
Today's Sponsor